BCM
MTNB icon

Bayesian Capital Management’s Matinas BioPharma MTNB Stock Holding History

Bayesian Capital Management’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-376
Closed -$4.07K – 1000
2023
Q4 		$4.07K Buy
+376
New +$4.24K ﹤0.01% 704

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
NRS
Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bayesian Capital Management's MTNB Position: Q1 2024 in Review

Bayesian Capital Management sold out of Matinas BioPharma (MTNB) in Q1 2024, closing a stake of 376 shares — an estimated $4.07K sold.

Bayesian Capital Management first reported a position in MTNB in Q4 2023 and held it in 1 quarter. The position peaked at $4.07K in Q4 2023. 42 funds tracked by Wall St. Rank hold MTNB as of Q1 2024.

  • Bayesian Capital Management reported no remaining Matinas BioPharma position as of Q1 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 376 Matinas BioPharma shares in Q1 2024, an estimated $4.07K.
  • Bayesian Capital Management first reported a position in Matinas BioPharma in Q4 2023 and held it in 1 quarter.
  • Bayesian Capital Management's Matinas BioPharma position peaked at $4.07K in Q4 2023.
  • 42 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2024.

Based on Bayesian Capital Management's 13F filing for Q1 2024, filed 15 May 2024.